1.36
+0.01(+0.74%)
Currency In USD
| Previous Close | 1.35 |
| Open | 1.35 |
| Day High | 1.4 |
| Day Low | 1.33 |
| 52-Week High | 16.94 |
| 52-Week Low | 1.26 |
| Volume | 93,811 |
| Average Volume | 334,588 |
| Market Cap | 35.58M |
| PE | -0.16 |
| EPS | -8.52 |
| Moving Average 50 Days | 1.7 |
| Moving Average 200 Days | 3.2 |
| Change | 0.01 |
If you invested $1000 in Senti Biosciences, Inc. (SNTI) since IPO date, it would be worth $13.63 as of September 16, 2025 at a share price of $1.36. Whereas If you bought $1000 worth of Senti Biosciences, Inc. (SNTI) shares 3 years ago, it would be worth $85 as of September 16, 2025 at a share price of $1.36.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 02, 2025 1:05 PM GMT
Live webcast presentation with Co-Founder and CEO, Dr. Timothy Lu, on September 8th at 2:00 PM ETSOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology co
Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
GlobeNewswire Inc.
Aug 14, 2025 1:15 PM GMT
Live video webcast on Tuesday, August 19th at 2:20 PM ETSOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and
Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia
GlobeNewswire Inc.
Aug 12, 2025 1:15 PM GMT
Access the “What This Means” segment here SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies